CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $192.51M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -0.73: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
164.78MEUR192.51M · vs all stocks (USD)
Revenue (TTM)
5.41MEUR6.32M · vs all stocks (USD)
Beta
0.8470xvs all stocks
52-Week Change
-53.71%vs all stocks
Market Capitalization
164.78MEUR192.51M · vs all stocks (USD)
Enterprise Value
78.01MEUR91.14M · vs all stocks (USD)
Forward P/E
-3.70xvs Biotechnology peers
Price to Sales (TTM)
30.56xvs Biotechnology peers
Price to Book (MRQ)
2.41xvs Biotechnology peers
Enterprise to Revenue
14.41xvs Biotechnology peers
Enterprise to EBITDA
-1.93xvs Biotechnology peers
Operating Margin
-494.49%vs Biotechnology peers
Return on Assets (TTM)
-31.80%vs Biotechnology peers
Return on Equity (TTM)
-80.85%vs Biotechnology peers
Revenue (TTM)
5.41MEUR6.32M · vs all stocks (USD)
Revenue per Share (TTM)
0.1160EURUpdated Aug 22, 2026Quarterly Revenue Growth
176.20%vs Biotechnology peers
Gross Profit (TTM)
4.38MEUR5.11M · vs all stocks (USD)
EBITDA (TTM)
-40.38MEUR-47.17M · vs all stocks (USD)
Net Income (TTM)
-41.79MEUR-48.82M · vs all stocks (USD)
Operating Cash Flow (TTM)
-39.07MEUR-45.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.79MEUR-27.79M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.78MEURFY2025 · Dec 31, 2025Cost of Goods Sold
1.04MEURFY2025 · Dec 31, 2025Gross Profit
2.74MEURFY2025 · Dec 31, 2025Operating Income
-40.92MEUR-47.80M · vs all stocks (USD)
Pre-tax Income
-41.48MEURFY2025 · Dec 31, 2025Income Tax Expense
311.00KEURFY2025 · Dec 31, 2025Net Income
-41.79MEURFY2025 · Dec 31, 2025EBIT
-39.26MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-37.88MEURFY2025 · Dec 31, 2025Research & Development
12.32MEURFY2025 · Dec 31, 2025Selling, General & Administrative
9.79MEURFY2025 · Dec 31, 2025Other Operating Expenses
3.01MEURFY2025 · Dec 31, 2025Non-operating Interest Income
580.00KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
2.22MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-41.03MEURFY2025 · Dec 31, 2025Free Cash Flow
-41.47MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.11MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.48MEURFY2025 · Dec 31, 2025Stock-based Compensation
2.64MEURFY2025 · Dec 31, 2025Other Non-cash Items
708.00KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.90MEURFY2025 · Dec 31, 2025Capital Expenditures
-432.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-432.00KEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
0.00EURFY2025 · Dec 31, 2025Net Financing Cash Flow
51.19MEURFY2025 · Dec 31, 2025Shares Outstanding
56.01MSharesUpdated Aug 22, 2026Float Shares
43.98MSharesUpdated Aug 22, 2026% Held by Insiders
28.48%vs all stocks
% Held by Institutions
23.58%vs all stocks
Total Cash (MRQ)
68.11MEUR79.57M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.22EURUpdated Aug 22, 2026Total Debt (MRQ)
13.66MEUR15.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2470xvs Biotechnology peers
Current Ratio (MRQ)
6.67xvs Biotechnology peers
Book Value per Share (MRQ)
0.9880EURUpdated Aug 22, 2026Total Assets
84.55MEUR98.78M · vs all stocks (USD)
Total Current Assets
74.08MEURFY2025 · Dec 31, 2025Total Liabilities
29.24MEURFY2025 · Dec 31, 2025Total Non-current Assets
10.48MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
18.14MEURFY2025 · Dec 31, 2025Total Current Liabilities
11.10MEURFY2025 · Dec 31, 2025Cash
9.05MEURFY2025 · Dec 31, 2025Cash Equivalents
59.05MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
68.11MEURFY2025 · Dec 31, 2025Inventory
803.00KEURFY2025 · Dec 31, 2025Accounts Payable
3.08MEURFY2025 · Dec 31, 2025Short-term Debt
538.00KEURFY2025 · Dec 31, 2025Long-term Debt
13.13MEURFY2025 · Dec 31, 2025Common Stock (Book)
6.72MEURFY2025 · Dec 31, 2025Retained Earnings
-222.56MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
55.32MEUR64.62M · vs all stocks (USD)
52-Week Low
2.27EURUpdated Aug 22, 202652-Week High
5.77EURUpdated Aug 22, 202652-Week Change
-53.71%vs all stocks
Beta
0.8470xvs all stocks
50-Day MA
2.49EURUpdated Aug 22, 2026200-Day MA
3.41EURUpdated Aug 22, 2026Avg 10-Day Volume
107.55KSharesUpdated Aug 22, 2026Avg 30-Day Volume
88.43KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.9000EURUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.67Altman Z-Score: -0.73
Financial Health
Altman Z-Score -0.73: distress zoneCritical
Altman Z-Score: -0.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $192.51M, lower than 95% of all stocks globallySignificant
Market cap (USD): 192,508,886.396Global P5: 269,387,740.27
Revenue is $6.32M, lower than 95% of all stocks globallySignificant
Revenue (USD): 6,324,959.64Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk